Aims Sodium-glucose cotransporter-2 inhibitors (SGLT2i) have been shown to have benefit
in patients with heart failure (HF). Multiple systematic reviews and meta-analyses (SRs and …

Aims We sought to conduct a meta‐analysis regarding the safety and efficacy of sodium‐
glucose co‐transporter 2 (SGLT2) inhibitors in patients with heart failure (HF). Methods and …

Aims Sodium-glucose co-transporter inhibitors (SGLT2i) are emerging as a new treatment
for heart failure (HF) after demonstrating favorable clinical outcomes in several randomized …

Abstract Sodium–glucose cotransporter‐2 inhibitors (SGLT2is) reduce morbidity and
mortality for heart failure (HF) patients and are recommended as cornerstones for their …

Background: Recent trials demonstrated the clinical efficacy of sodium–glucose
cotransporter-2 inhibitors (SGLT2i) in patients with heart failure (HF), regardless of the …

Background Sodium–glucose cotransporter 2 (SGLT2) inhibitors reduce the composite of
heart failure (HF) hospitalizations or cardiovascular mortality among patients with HF …

Background Heart failure (HF) prognosis without therapy is poor, however introduction of a
range of drugs has improved it. We aimed to perform a systematic review on the effects and …

Heart failure remains a leading cause of hospitalization and death, and presents a
significant challenge for healthcare providers despite the advancements in its management …

Background: Sodium-glucose cotransporter 2 (SGLT2) inhibitors have shown promise in
improving cardiovascular outcome in patients with heart failure (HF) and diabetes mellitus …

Background To investigate the overall effect of sodium-glucose cotransporter-2 inhibitors
(SGLT-2i) on cardiovascular outcomes in a broad spectrum of heart failure (HF) patients …